Glaukos Corp.
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About Glaukos Corp.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
/ 
Frequently asked questions
To buy Glaukos Corp. stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Glaukos Corp. by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Glaukos Corp. is GKOS:xnys. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Glaukos Corp. has its primary listing on New York Stock Exchange. You can trade Glaukos Corp. with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Glaukos Corp. is available to trade on SaxoInvestor and SaxoTrader. You can buy shares directly and include Glaukos Corp. as part of a broader investment portfolio.
Learn more about investing and trading in Saxo's education hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures—so you can make more informed decisions when considering shares like Glaukos Corp..